Aligos Therapeutics (ALGS) Total Liabilities (2019 - 2026)
Aligos Therapeutics' (ALGS) quarterly Total Liabilities came in at $32.8 million in Q1 2026, down 4.34% YoY from $34.3 million in Q1 2025, and down 6.34% on a QoQ basis from $35.0 million in Q4 2025.
Aligos Therapeutics (ALGS) Total Liabilities (2019 - 2026) Analysis & Trends
Aligos Therapeutics (ALGS) has 8 years of Total Liabilities data on file, last reported at $32.8 million in Q1 2026.
- Quarterly Total Liabilities fell 4.34% year-over-year to $32.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32.8 million (down 4.34% YoY) and the FY2025 annual result came in at $35.0 million, down 64.68% from the prior year.
- Total Liabilities declined to $32.8 million in Q1 2026, from $35.0 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $99.1 million in Q4 2024 to a low of $31.0 million in Q3 2023.
- A 5-year average of $45.4 million and a median of $38.3 million in 2024 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2024 — Total Liabilities soared 84.13% — and 2025, when it sank 64.68%.
- Tracing ALGS's Total Liabilities over 5 years: stood at $42.8 million in 2022, then surged by 38.92% to $59.4 million in 2023, then jumped by 66.65% to $99.1 million in 2024, then sank by 64.68% to $35.0 million in 2025, then declined by 6.34% to $32.8 million in 2026.
- The last three Total Liabilities figures came in at $32.8 million (Q1 2026), $35.0 million (Q4 2025), and $37.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Aligos Therapeutics | 67.38 Mn | 36.94 Mn | - | 34.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 34.44 Mn |
| Mar 31, 2026 | 32.77 Mn |
| Dec 31, 2025 | 34.99 Mn |
| Sep 30, 2025 | 37.93 Mn |
| Jun 30, 2025 | 32.84 Mn |
| Mar 31, 2025 | 34.25 Mn |
| Dec 31, 2024 | 99.07 Mn |
| Sep 30, 2024 | 38.33 Mn |
| Jun 30, 2024 | 41.58 Mn |
| Mar 31, 2024 | 68.11 Mn |
| Dec 31, 2023 | 59.45 Mn |
| Sep 30, 2023 | 31.03 Mn |
| Jun 30, 2023 | 36.50 Mn |
| Mar 31, 2023 | 36.99 Mn |
| Dec 31, 2022 | 42.79 Mn |
| Sep 30, 2022 | 42.06 Mn |
| Jun 30, 2022 | 45.54 Mn |
| Mar 31, 2022 | 57.58 Mn |
| Dec 31, 2021 | 50.64 Mn |
| Sep 30, 2021 | 46.06 Mn |